Background Oral anticoagulants (OACs) mitigate the risk of stroke in atrial fibrillation (AF)
patients. Objective Elderly AF patients who were treated with OACs (apixaban, dabigatran …

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are more commonly
used to prevent atrial fibrillation (AF) patients from thromboembolic events than vitamin K …

Abstract Background Direct oral anticoagulants (DOACs) have high potency against their
therapeutic target and are widely used in the treatment of atrial fibrillation (AF). Most DOACs …

East Asians are reportedly at high risk of anticoagulant-related bleeding; therefore, some
physicians prefer to prescribe low-dose direct oral anticoagulants (DOACs). Little is known …

Introduction: Patients with non-valvular atrial fibrillation (NVAF) may be prescribed warfarin
or a non–vitamin K oral anticoagulant (NOAC). There is increasing evidence that NOACs are …

Abstract Background Direct oral anticoagulants (DOACs) have been proven to be effective
and safe for prevention of ischemic stroke and systemic embolism in patients with non …

BACKGROUND Most of the randomized clinical trials that led to the wide use of non-vitamin
K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation (AF) …

Background and aim Direct oral anticoagulants (DOACs) became a widespread alternative
in anticoagulant therapy. Nevertheless, concerns are raised about their safety, with …

We investigated the prevalence of retinal vascular occlusion and intraocular bleeding and
compare their risks in patients undergoing anticoagulant therapy, either with non-vitamin K …

Aims This study aimed to evaluate the performance of HAS‐BLED and ORBIT scores in
predicting bleeding risk among Asian patients with nonvalvular atrial fibrillation (NVAF) …